title: Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
abstract: Stored serum specimens, from four regions of Thailand, of healthy children attending well baby clinics and of healthy people with acute illnesses visiting outpatient clinics were randomly sampled and tested for IgG antibody to measles, mumps, and rubella (MMR). The immunity patterns of rubella and mumps fitted well with the history of rubella and MMR vaccination, seroprotective rates being over 85% among those aged over seven years. A high proportion of younger children acquired the infection before the age of vaccination. MMR vaccination should preferably be given to children at an earlier age. For measles, 73% seroprotective rates among children, aged 8-14 years, who should have received two doses of measles/MMR vaccine, were lower than expected. This finding was consistent with the age-group reported in outbreaks of measles in Thailand. The apparent ineffectiveness (in relation to measles) of MMR immunization of 1st grade students warrants further studies.
authors.affiliation: Bureau of General Communicable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. piyanit@health.moph.go.th
authors.forename: Piyanit
authors.initials: P
authors.lastname: Tharmaphornpilas
authors.forename: Pornsak
authors.initials: P
authors.lastname: Yoocharean
authors.forename: Aim-Orn
authors.initials: AO
authors.lastname: Rasdjarmrearnsook
authors.forename: Apiradee
authors.initials: A
authors.lastname: Theamboonlers
authors.forename: Yong
authors.initials: Y
authors.lastname: Poovorawan
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D017589:Immunization Programs; D008297:Male; D008457:Measles / Q000453:epidemiology; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D009107:Mumps / Q000453:epidemiology; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000276:immunology; D009109:Mumps virus / Q000276:immunology; D012409:Rubella / Q000453:epidemiology; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology; D016036:Seroepidemiologic Studies; D013785:Thailand / Q000453:epidemiology; D013997:Time Factors; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined; C040901:rubella antibodies